1
|
Kawana-Tachikawa A, Llibre JM, Bravo I, Escrig R, Mothe B, Puig J, Puertas MC, Martinez-Picado J, Blanco J, Manzardo C, Miro JM, Iwamoto A, Pozniak AL, Gatell JM, Clotet B, Brander C. Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals. PLoS One 2014; 9:e87334. [PMID: 24475275 PMCID: PMC3903883 DOI: 10.1371/journal.pone.0087334] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2013] [Accepted: 12/19/2013] [Indexed: 01/22/2023] Open
Abstract
Background The effect of maraviroc on the maintenance and the function of HIV-1-specific T cell responses remains unknown. Methods Subjects recently infected with HIV-1 were randomized to receive anti-retroviral treatment with or without maraviroc intensification for 48 weeks, and were monitored up to week 60. PBMC and in vitro-expanded T cells were tested for responses to the entire HIV proteome by ELISpot analyses. Intracellular cytokine staining assays were conducted to monitor the (poly)-functionality of HIV-1-specific T cells. Analyses were performed at baseline and week 24 after treatment start, and at week 60 (3 months after maraviroc discontinuation). Results Maraviroc intensification was associated with a slower decay of virus-specific T cell responses over time compared to the non-intensified regimen in both direct ex-vivo as well as in in-vitro expanded cells. The effector function profiles of virus-specific CD8+ T cells were indistinguishable between the two arms and did not change over time between the groups. Conclusions Maraviroc did not negatively impact any of the measured parameters, but was rather associated with a prolonged maintenance of HIV-1-specific T cell responses. Maraviroc, in addition to its original effect as viral entry inhibitor, may provide an additional benefit on the maintenance of virus-specific T cells which may be especially important for future viral eradication strategies.
Collapse
Affiliation(s)
- Ai Kawana-Tachikawa
- Irsicaixa AIDS Research Institute – HIVACAT, Autonomous University of Barcelona, Badalona, Spain
- Division of Infectious Diseases, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Josep M. Llibre
- Lluita contra la SIDA Foundation, HIV Unit, University Hospital Germans Trias i Pujol, Badalona, UAB, Badalona, Spain
| | - Isabel Bravo
- Lluita contra la SIDA Foundation, HIV Unit, University Hospital Germans Trias i Pujol, Badalona, UAB, Badalona, Spain
| | - Roser Escrig
- Lluita contra la SIDA Foundation, HIV Unit, University Hospital Germans Trias i Pujol, Badalona, UAB, Badalona, Spain
| | - Beatriz Mothe
- Irsicaixa AIDS Research Institute – HIVACAT, Autonomous University of Barcelona, Badalona, Spain
- Lluita contra la SIDA Foundation, HIV Unit, University Hospital Germans Trias i Pujol, Badalona, UAB, Badalona, Spain
- University of Vic, Vic, Spain
| | - Jordi Puig
- Lluita contra la SIDA Foundation, HIV Unit, University Hospital Germans Trias i Pujol, Badalona, UAB, Badalona, Spain
| | - Maria C. Puertas
- Irsicaixa AIDS Research Institute – HIVACAT, Autonomous University of Barcelona, Badalona, Spain
| | - Javier Martinez-Picado
- Irsicaixa AIDS Research Institute – HIVACAT, Autonomous University of Barcelona, Badalona, Spain
- University of Vic, Vic, Spain
- Institució Catalana de Recerca i Estudis Avancats (ICREA), Barcelona, Spain
| | - Julia Blanco
- Irsicaixa AIDS Research Institute – HIVACAT, Autonomous University of Barcelona, Badalona, Spain
- University of Vic, Vic, Spain
| | | | - Jose M. Miro
- Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain
| | - Aikichi Iwamoto
- Division of Infectious Diseases, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Anton L. Pozniak
- HIV/GUM Department, Chelsea and Westminster Hospital, London, United Kingdom
| | - Jose M. Gatell
- Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain
| | - Bonaventura Clotet
- Irsicaixa AIDS Research Institute – HIVACAT, Autonomous University of Barcelona, Badalona, Spain
- Lluita contra la SIDA Foundation, HIV Unit, University Hospital Germans Trias i Pujol, Badalona, UAB, Badalona, Spain
- University of Vic, Vic, Spain
| | - Christian Brander
- Irsicaixa AIDS Research Institute – HIVACAT, Autonomous University of Barcelona, Badalona, Spain
- University of Vic, Vic, Spain
- Institució Catalana de Recerca i Estudis Avancats (ICREA), Barcelona, Spain
- * E-mail:
| | | |
Collapse
|